Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
IMM-27M by ImmuneOnco Biopharmaceuticals (Shanghai) for Breast Cancer: Likelihood of Approval
IMM-27M is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase II for Breast Cancer. According to GlobalData,...